Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 326 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Body CT Scan Clear all
Completed Not applicable Interventional Results available

Patterns and Prevalence of FDG Extravasation in PET/CT Scans

NCT03041090
View directory record Official record
Conditions
Intravenous Infiltration
Interventions
Lucerno ID (identification) System
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 18, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

NCT04432597
View directory record Official record
Conditions
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer, Cervical Cancer
Interventions
PRGN-2009, M7824, EKG, CT Scan, Brain MRI, Biopsy
Biological · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional

UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning

NCT06465966
View directory record Official record
Conditions
Prostate Cancer
Interventions
iRAI
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Not listed Not applicable Interventional

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

NCT05823402
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
SPECT/CT
Diagnostic Test
Lead sponsor
BAMF Health
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 18, 2026, 5:13 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Tenecteplase in Wake-up Ischaemic Stroke Trial

NCT03181360
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Acute
Interventions
Tenecteplase, Control
Drug · Other
Lead sponsor
University Hospital of North Norway
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 18, 2026, 5:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

NCT07225985
View directory record Official record
Conditions
Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Bendamustine, Pralatrexate, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Magnetic Resonance Imaging, Multigated Acquisition Scan, Peripheral Blood Stem Cell Transplantation, Positron Emission Tomography, Questionnaire Administration, Total-Body Irradiation, Biospecimen Collection
Drug · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Active, not recruiting Not applicable Interventional

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

NCT01582204
View directory record Official record
Conditions
Renal Cancer
Interventions
124IcG250
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Active, not recruiting Phase 4 Interventional

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

NCT06074510
View directory record Official record
Conditions
Prostate Cancer
Interventions
Piflufolastat F 18 Intravenous Solution [PYLARIFY]
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 18, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional Results available

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

NCT04975516
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Recurrent Pancreatic Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
Interventions
Chemotherapy, Stereotactic Body Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Results available

PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer

NCT02837263
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Metastatic Carcinoma in the Liver
Interventions
Stereotactic body radiotherapy (SBRT), Pembrolizumab
Radiation · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Imaging Apoptosis for Lymphoma Treatment Response

NCT05048732
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
18F-FluorApoTrace
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 18, 2026, 5:13 AM EDT
Completed Phase 3 Interventional

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer

NCT02615067
View directory record Official record
Conditions
Prostate Cancer
Interventions
99mTc-MIP-1404 Injection, Whole-Body Planar and pelvic SPECT/CT scan
Drug · Diagnostic Test
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 18, 2026, 5:13 AM EDT
Recruiting Phase 2 Interventional

Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)

NCT06436612
View directory record Official record
Conditions
Abdominopelvic Sarcomas
Interventions
Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional

PSMA PET for Surveillance After Focal Therapy

NCT07115914
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Cancer Metastatic Disease
Interventions
PSMA PET/CT scan
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Results available

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

NCT03388619
View directory record Official record
Conditions
Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate, Prostatic Cancer
Interventions
Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan, 18F-NaF PET Imaging, CT, mpMRI, ADT
Radiation · Diagnostic Test · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

NCT02865434
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection), Whole body planar SPECT imaging (15 Minutes post-injection), Whole body planar SPECT imaging (60 Minutes post-injection), Whole body planar SPECT imaging (180 Minutes post-injection), Whole body planar SPECT imaging (18-20 Hours post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after injection), Blood Collection for PK Testing (15 minutes post injection), Blood Collection for PK Testing (60 minutes post injection), Blood Collection for PK Testing (180 minutes post injection), Blood Collection for PK Testing (18-20 hours post injection), Planar Image with both Hands in Field of View
Drug · Procedure
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 18, 2026, 5:13 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Validation of a Body-Composition Segmentation Software on a Diverse Public CT Scan Cohort

NCT07600866
View directory record Official record
Conditions
Sarcopenia, Body Composition, Obesity
Interventions
Soma Body-Composition Segmentation Software
Diagnostic Test
Lead sponsor
Nucleo Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT01313572
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 18, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

NCT07621614
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
Interventions
Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
5
States / cities
Oakland, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Terminated Not applicable Interventional Results available

Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

NCT01799135
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
DCE-MRI scan, Stereotactic Body Radiation Therapy, 4D-CT scan
Other · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 18, 2026, 5:13 AM EDT
Recruiting No phase listed Observational

A Study of a New PET Scanner in People With Cancer

NCT07690917
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer, Prostate Cancer
Interventions
Biograph Vision Quadra scanner, PET/CT
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Recruiting No phase listed Observational

Multidimensional Phenotype Classification in Grade 3 Bronchopulmonary Dysplasia

NCT06475976
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Chest computed tomography (CT) with angiography, Bronchoscopy with bronchoalveolar lavage, Echocardiography, 24 hour esophageal pH ("potential of hydrogen") - multichannel intraluminal impedance (MII) monitoring (reflux testing)
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 1 Year
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Recruiting Phase 1 Interventional

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT06479811
View directory record Official record
Conditions
Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma, Somatostatin Receptor Positive, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Kidney Cancers, Head and Neck Tumors, Gastrointestinal Neuroendocrine Tumors
Interventions
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 18, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia

NCT03736564
View directory record Official record
Conditions
Osteomalacia
Interventions
68Ga-DOTATATE PET/CT
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 18, 2026, 5:13 AM EDT